Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Wake Forest University Health Sciences
UNICANCER
Brigham and Women's Hospital
Hoffmann-La Roche
M.D. Anderson Cancer Center
Sapience Therapeutics
M.D. Anderson Cancer Center
Melanoma Institute Australia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Seattle Children's Hospital
GlaxoSmithKline
University of Zurich
HUYABIO International, LLC.
Emory University
Dana-Farber Cancer Institute
NGM Biopharmaceuticals, Inc
SkylineDx